SOHO State of the Art Updates and Next Questions: Recent advances in CAR-T cell therapy for Non-Hodgkin lymphoma

Publication date: Available online 2 October 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Avyakta Kallam, Julie M. VoseAbstractNon-Hodgkin lymphomas that are refractory to or relapse after frontline chemoimmunotherapy have a poor prognosis. Although high dose chemotherapy, followed by autologous stem cell transplantation remains the standard of care at relapse, this treatment modality leads to a cure in less than 50% of the patients. Adoptive cellular immunotherapy with anti CD 19 chimeric antigen receptor (CAR) T cell has changed the treatment landscape in B cell lymphomas. They have emerged as effective therapy in patients with multiple relapsed/refractory disease, capable of sustaining durable remissions. Two CAR-T cell products (axicabtagene ciloleucel and tisagenlecleucel) are currently approved by the FDA. A third anti CD 19 CAR-T cell, lisocabtagene ciloleucel is currently being evaluated in large clinical trials and may also be FDA approved. CAR- T cell related toxicities, including infections, cytokine release syndrome and neurotoxicity are potential complications of therapy. Ongoing research aims to improve the safety, efficacy of this therapy. In this review, we will summarize CAR -T cell therapy, their limitations and recent developments.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research